Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Lennar Corporation (LEN) vs Viatris Inc (VTRS) Price & Performance

Lennar CorporationTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Lennar Corporation vs Viatris Inc — how do they compare? Lennar Corporation trades at $76.69 (market cap $18.44B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Lennar Corporation and Viatris Inc are close in size by market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Lennar Corporation for 67 Days and Viatris Inc for 57 Days on average.

LENVTRS
Market Cap
$18.44B$20.03B
Volume
6,012,21414,109,977
Sector
Consumer CyclicalHealth
52-Week High
$133.13$18.27
52-Week Low
$74.44$9.74
Typical Hold Time
67 Days57 Days
Enterprise Value
$22.86B$32.15B
Dividend Yield
2.58%2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Lennar Corporation

Lennar (LEN) trades at $77.6, up 1.93% on the day, but remains in a bearish technical trend with recent earnings misses and declining profitability. The stock is trading below its book value with a P/B of 0.86, indicating potential undervaluation, while Berkshire Hathaway's increasing stake to 11.2% provides notable institutional support. Revenue and net income have softened in 2025, with margins under pressure amid a challenging housing market.

The outlook is mixed: strong institutional backing and attractive valuation metrics suggest long-term opportunity, but near-term headwinds from rising mortgage rates, earnings volatility, and bearish technical signals pose risks. Analyst consensus is divided, with a $77.38 price target slightly below the current price, reflecting cautious optimism amid sector uncertainty.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

LEN

No sentiment data available yet.

VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About Lennar Corporation

Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.

Read more on LEN →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →